Drug Profile
Sarakalim
Alternative Names: BIIX1XX; RS 91309Latest Information Update: 30 Jan 2007
Price :
$50
*
At a glance
- Originator Roche Palo Alto LLC
- Developer Boehringer Ingelheim; Roche Palo Alto
- Class Benzopyrans; Muscle relaxants; Small molecules
- Mechanism of Action Potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma